The effects of rate and rhythm control on blood pressure and antihypertensive drug usage in patients with atrial fibrillation and hypertension enrolled in the AFFIRM trial

Journal of Cardiovascular Electrophysiology

Volumn 21, Issue 10, 2010, Pages 1094-1098

  Masood, Syed O ^a   Wasmund, Stephen L ^a   Akoum, Nazem W ^a   Egger, Marlene J ^a   Hsiai, Tzung ^b   Hamdan, Mohamed H ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

Author keywords

AFFIRM study; atrial fibrillation; hypertension; rate control; rhythm control

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DILTIAZEM; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; VERAPAMIL;

AGED; ANTIHYPERTENSIVE THERAPY; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE MONITORING; BLOOD PRESSURE REGULATION; CLINICAL EVALUATION; COMPARATIVE STUDY; CORRELATION ANALYSIS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; FEMALE; HEART ATRIUM FIBRILLATION; HEART RATE; HEART RHYTHM; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT PLANNING;

AGED; ANTIHYPERTENSIVE AGENTS; ATRIAL FIBRILLATION; BLOOD PRESSURE; CAUSALITY; COMORBIDITY; FEMALE; HEART RATE; HUMANS; HYPERTENSION; MALE; RISK ASSESSMENT; RISK FACTORS; TREATMENT OUTCOME; UNITED STATES;

EID: 78649270048     PISSN: 10453873     EISSN: 15408167     Source Type: Journal    
DOI: 10.1111/j.1540-8167.2010.01792.x     Document Type: Article

References (33)

1. Go AS, Hylek EM, Phillips KA, Chang Y, Henault LE, Selby JV, Singer DE,: Prevalence of diagnosed atrial fibrillation in adults: National implications for rhythm management and stroke prevention: The AnTicoagulation and Risk Factors in Atrial Fibrillation (ATRIA) Study. JAMA 2001; 285: 2370-2375.
2. Miyasaka Y, Barnes ME, Gersh BJ, Cha SS, Bailey KR, Abhayaratna WP, Seward JB, Tsang TS,: Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence. Circulation 2006; 114: 119-125.
3. Burt VL, Cutler JA, Higgins M, Horan MJ, Labarthe D, Whelton P, Brown C, Roccella EJ,: Trends in the prevalence, awareness, treatment, and control of hypertension in the adult US population. Data from the health examination surveys, 1960 to 1991. Hypertension 1995; 26: 60-69.
4. Verdecchia P, Reboldi G, Gattobigio R, Bentivoglio M, Borgioni C, Angeli F, Carluccio E, Sardone MG, Porcellati C,: Atrial fibrillation in hypertension: Predictors and outcome. Hypertension 2003; 41: 218-223.
5. Boldt A, Wetzel U, Weigl J, Garbade J, Lauschke J, Hindricks G, Kottkamp H, Gummert JF, Dhein S,: Expression of angiotensin II receptors in human left and right atrial tissue in atrial fibrillation with and without underlying mitral valve disease. J Am Coll Cardiol 2003; 42: 1785-1792.
6. Dixen U, Ravn L, Soeby-Rasmussen C, Paulsen AW, Parner J, Frandsen E, Jensen GB,: Raised plasma aldosterone and natriuretic peptides in atrial fibrillation. Cardiology 2007; 108: 35-39.
7. Goette A, Staack T, Rocken C, Arndt M, Geller JC, Huth C, Ansorge S, Klein HU, Lendeckel U,: Increased expression of extracellular signal-regulated kinase and angiotensin-converting enzyme in human atria during atrial fibrillation. J Am Coll Cardiol 2000; 35: 1669-1677.
8. Freestone B, Chong AY, Nuttall S, Lip GY,: Impaired flow mediated dilatation as evidence of endothelial dysfunction in chronic atrial fibrillation: Relationship to plasma von Willebrand factor and soluble E-selectin levels. Thromb Res 2008; 122: 85-90.
9. Nikitovic D, Zacharis EA, Manios EG, Malliaraki NE, Kanoupakis EM, Sfiridaki KI, Skalidis EI, Margioris AN, Vardas PE,: Plasma levels of nitrites/nitrates in patients with chronic atrial fibrillation are increased after electrical restoration of sinus rhythm. J Interv Card Electrophysiol 2002; 7: 171-176.
10. Takahashi N, Ishibashi Y, Shimada T, Sakane T, Ohata S, Sugamori T, Ohta Y, Inoue S, Nakamura K, Shimizu H, Katoh H, Murakami Y,: Impaired exercise-induced vasodilatation in chronic atrial fibrillation-role of endothelium-derived nitric oxide. Circ J 2002; 66: 583-588.
11. Takahashi N, Ishibashi Y, Shimada T, Sakane T, Ohata S, Sugamori T, Ohta Y, Inoue S, Nakamura K, Shimizu H, Katoh H, Sano K, Murakami Y, Hashimoto M,: Atrial fibrillation impairs endothelial function of forearm vessels in humans. J Card Fail 2001; 7: 45-54.
12. Segerson NM, Sharma N, Smith ML, Wasmund SL, Kowal RC, Abedin M, MacGregor JF, Pai RK, Freedman RA, Klein RC, Wall TS, Stoddard GJ, Hamdan MH,: The effects of rate and irregularity on sympathetic nerve activity in human subjects. Heart Rhythm 2007; 4: 20-26.
13. Wasmund SL, Li JM, Page RL, Joglar JA, Kowal RC, Smith ML, Hamdan MH,: Effect of atrial fibrillation and an irregular ventricular response on sympathetic nerve activity in human subjects. Circulation 2003; 107: 2011-2015.
14. Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD,: A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 2002; 347: 1825-1833.
15. The Planning and Steering Committees of the AFFIRM study for the NHLBI AFFIRM investigators: Atrial fibrillation follow-up investigation of rhythm managementâthe AFFIRM study design. Am J Cardiol 1997; 79: 1198-1202.
16. Ducharme A, Swedberg K, Pfeffer MA, Cohen-Solal A, Granger CB, Maggioni AP, Michelson EL, McMurray JJ, Olsson L, Rouleau JL, Young JB, Yusuf S,: Prevention of atrial fibrillation in patients with symptomatic chronic heart failure by candesartan in the Candesartan in Heart failure: Assessment of Reduction in Mortality and morbidity (CHARM) program. Am Heart J 2006; 151: 985-991.
17. Hansson L, Lindholm LH, Ekbom T, Dahlof B, Lanke J, Schersten B, Wester PO, Hedner T, De Faire U,: Randomised trial of old and new antihypertensive drugs in elderly patients: Cardiovascular mortality and morbidity the Swedish Trial in Old Patients with Hypertension-2 study. Lancet 1999; 354: 1751-1756.
18. Hansson L, Lindholm LH, Niskanen L, Lanke J, Hedner T, Niklason A, Luomanmaki K, Dahlof B, De Faire U, Morlin C, Karlberg BE, Wester PO, Bjorck JE,: Effect of angiotensin-converting-enzyme inhibition compared with conventional therapy on cardiovascular morbidity and mortality in hypertension: The Captopril Prevention Project (CAPPP) randomised trial. Lancet 1999; 353: 611-616. (Pubitemid 29087980)
19. Healey JS, Baranchuk A, Crystal E, Morillo CA, Garfinkle M, Yusuf S, Connolly SJ,: Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: A meta-analysis. J Am Coll Cardiol 2005; 45: 1832-1839.
20. Madrid AH, Bueno MG, Rebollo JM, Marin I, Pena G, Bernal E, Rodriguez A, Cano L, Cano JM, Cabeza P, Moro C,: Use of irbesartan to maintain sinus rhythm in patients with long-lasting persistent atrial fibrillation: A prospective and randomized study. Circulation 2002; 106: 331-336.
21. Madrid AH, Marin IM, Cervantes CE, Morell EB, Estevez JE, Moreno G, Parajon JR, Peng J, Limon L, Nannini S, Moro C,: Prevention of recurrences in patients with lone atrial fibrillation. The dose-dependent effect of angiotensin II receptor blockers. J Renin Angiotensin Aldosterone Syst 2004; 5: 114-120.
22. Maggioni AP, Latini R, Carson PE, Singh SN, Barlera S, Glazer R, Masson S, Cere E, Tognoni G, Cohn JN,: Valsartan reduces the incidence of atrial fibrillation in patients with heart failure: Results from the Valsartan Heart Failure Trial (Val-HeFT). Am Heart J 2005; 149: 548-557.
23. Pedersen OD, Bagger H, Kober L, Torp-Pedersen C,: The occurrence and prognostic significance of atrial fibrillation/-flutter following acute myocardial infarction. TRACE Study group. TRAndolapril Cardiac Evalution. Eur Heart J 1999; 20: 748-754.
24. Pizzetti F, Turazza FM, Franzosi MG, Barlera S, Ledda A, Maggioni AP, Santoro L, Tognoni G,: Incidence and prognostic significance of atrial fibrillation in acute myocardial infarction: The GISSI-3 data. Heart 2001; 86: 527-532.
25. Ueng KC, Tsai TP, Yu WC, Tsai CF, Lin MC, Chan KC, Chen CY, Wu DJ, Lin CS, Chen SA,: Use of enalapril to facilitate sinus rhythm maintenance after external cardioversion of long-standing persistent atrial fibrillation. Results of a prospective and controlled study. Eur Heart J 2003; 24: 2090-2098.
26. Van Den Berg MP, Crijns HJ, Van Veldhuisen DJ, Griep N, De Kam PJ, Lie KI,: Effects of lisinopril in patients with heart failure and chronic atrial fibrillation. J Card Fail 1995; 1: 355-363.
27. Vermes E, Tardif JC, Bourassa MG, Racine N, Levesque S, White M, Guerra PG, Ducharme A,: Enalapril decreases the incidence of atrial fibrillation in patients with left ventricular dysfunction: Insight from the Studies Of Left Ventricular Dysfunction (SOLVD) trials. Circulation 2003; 107: 2926-2931. (Pubitemid 36736634)
28. Wachtell K, Lehto M, Gerdts E, Olsen MH, Hornestam B, Dahlof B, Ibsen H, Julius S, Kjeldsen SE, Lindholm LH, Nieminen MS, Devereux RB,: Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study. J Am Coll Cardiol 2005; 45: 712-719.
29. Cardin S, Li D, Thorin-Trescases N, Leung TK, Thorin E, Nattel S,: Evolution of the atrial fibrillation substrate in experimental congestive heart failure: Angiotensin-dependent and -independent pathways. Cardiovasc Res 2003; 60: 315-325.
30. Goette A, Hoffmanns P, Enayati W, Meltendorf U, Geller JC, Klein HU,: Effect of successful electrical cardioversion on serum aldosterone in patients with persistent atrial fibrillation. Am J Cardiol 2001; 88: 906-909.
31. Buga GM, Gold ME, Fukuto JM, Ignarro LJ,: Shear stress-induced release of nitric oxide from endothelial cells grown on beads. Hypertension 1991; 17: 187-193.
32. Noris M, Morigi M, Donadelli R, Aiello S, Foppolo M, Todeschini M, Orisio S, Remuzzi G, Remuzzi A,: Nitric oxide synthesis by cultured endothelial cells is modulated by flow conditions. Circ Res 1995; 76: 536-543.
33. Rubanyi GM, Romero JC, Vanhoutte PM,: Flow-induced release of endothelium-derived relaxing factor. Am J Physiol 1986; 250: H1145-H1149.